Comparative Pharmacology
Head-to-head clinical analysis: ANNOVERA versus HER STYLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANNOVERA versus HER STYLE.
ANNOVERA vs HER STYLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive containing segesterone acetate, a progestin, and ethinyl estradiol, an estrogen. Segesterone acetate suppresses gonadotropin release, preventing ovulation; ethinyl estradiol contributes to contraceptive efficacy by stabilizing the endometrium and inhibiting gonadotropin secretion.
HER STYLE is a hormonal contraceptive containing ethinyl estradiol and levonorgestrel. It inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion. It also thickens cervical mucus to impede sperm penetration and alters endometrial lining to prevent implantation.
One vaginal ring inserted and left in place for 3 weeks, followed by a 1-week ring-free interval. Each ring releases ethinyl estradiol 0.024 mg/day and segesterone acetate 0.15 mg/day over 21 days.
Not applicable. HER STYLE is not a recognized pharmaceutical agent; no standard dosing available.
None Documented
None Documented
Terminal half-life of etonogestrel (ENG): ~25 hours; ethinylestradiol (EE): ~12 hours; steady-state achieved after 7-14 days.
Terminal half-life: 12 hours (range 10–14 hours). Clinical context: Allows twice-daily dosing; steady-state achieved in ~2.5 days.
Renal: ~60% as metabolites; fecal: ~35% as metabolites; biliary: minor.
Renal: 70% unchanged; Fecal: 20% as metabolites; Biliary: 10%.
Category C
Category C
Contraceptive
Contraceptive